ASH 2018 | Is CLL chemoimmunotherapy finished?
Robin Foà
Robin Foà, MD, of Sapienza University of Rome, Rome, Italy, gives us his take on the key chronic lymphocytic leukemia (CLL) highlights from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Prof. Foà highlights novel agents changing the treatment landscape.
Related videos
3:37 Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery
3:37 Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
3:37 An exciting era for CAR T-cell therapy
Mohamad Mohty
3:37 Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
3:37 JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
